Compare iShares MSCI Canada (TSX) (EWC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $7.14B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.7× iShares MSCI Canada (TSX)'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EWC | REGN | |
|---|---|---|
Market Cap | $7.14B | $76.40B |
Volume | 2,496,812 | 626,381 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $852.03 |
52-Week Low | $49.72 | $557.73 |
Typical Hold Time | 57 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
